Document resource
Background/Objectives To validate a novel patient-reported outcome measure, the Seizure-Related Impact Assessment Scale (SERIAS). It captures epilepsy-related disability, and is intended for use in epilepsy clinical trials and practice.Methods Prospective longitudinal study of adults with epilepsy recruited from an Australian Comprehensive Epilepsy Centre. Participants completed SERIAS at baseline, and 3- and 6-months later. SERIAS has 6 self-report items; 5 items record the number of days per month impacted by seizures or treatment-related adverse effects, and 1 item is an epilepsy disability visual analogue scale. Higher SERIAS scores indicate greater disability. SERIAS was completed alongside instruments measuring seizure- and treatment-related adverse effects (WSAS, LAEP), mood disorders (NDDI-E, GAD-7), somatic symptoms (SSS-8), and quality of life (QOLIE-31, EQ-5D).Results 90 patients ( n=58 females, mean age 43.1 years) completed baseline SERIAS. Greater disability was negatively correlated with QOLIE-31 total score (b=-0.17, 95% CI [-0.27, -0.07]), and positively correlated with scores on EQ-5D-5L (b=0.15, 95% CI [0.04, 0.25]), NDDI-E (b=0.22, 95% CI [0.13, 0.31]), GAD-7 (b=0.21, 95% CI [0.09, 0.32]), SSS8 (b=0.29, 95% CI [0.17, 0.41]), LAEP (b=0.29, 95% CI [0.20, 0.39]), WSAS seizure-related adverse events (b=0.23, 95% CI [0.14, 0.33]), and WSAS treatment-related adverse events (b=0.36, 95% CI [0.26, 0.46]). Higher seizure frequency was associated with higher SERIAS score (b=0.07, 95% CI [0.03, 0.11]). Psychometric reliability for the SERIAS was acceptable (all coefficients >0.70) as was test-retest reliability (n=35 patients, ICC=0.72, 95% CI [0.51, 0.85]).Conclusion These findings suggest that SERIAS is a valid scale to measure epilepsy related disability.